Navigation Links
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Date:2/16/2012

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ --

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90) inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in the second quarter of 2012.

"Our team has been very pleased with the development of Debio 0932, which has become an important molecule in Debiopharm's pipeline," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We believe that HSP90 represents an important molecular target in cancer therapy, and we are eager to advance this molecule in the Phase Ib clinical trial, as well in our planned Phase I/II studies, which we hope will yield important new data for the further development of Debio 0932."

"We have been highly impressed with the depth of Debiopharm's development expertise and commitment to furthering Debio 0932 into additional clinical studies in 2012," said Dan Passeri, Curis President and Chief Executive Officer. "Importantly, we continue to be very pleased with the clinical results that have been observed to-date, and we look forward to reporting further progress on this molecule in the future."

About the Phase I Clinical Trial

Debiopharm initiated a Phase I clinical trial in April 2010 that was designed to evaluate the maximum tolerated dose and safety of Debio 0932. The first part of the study (Phase Ia), an open-label,
'/>"/>

SOURCE The Debiopharm Group and Curis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
2. Continuity as Debiopharm Group™ Management Moves Forward
3. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
4. Debiopharm Group™ and Aurigene Nominate Development Candidate
5. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
6. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
7. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
11. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... /PRNewswire-iReach/ -- Dr. Michael Gabriel of a prominent ... a recent study, which shows how grief in pregnancy may ... According to US News , ... likely than others to grow up overweight or obese, even ... were two specific types of stress that caused obesity: "Children ...
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of ... including next-generation sequencing (NGS) gene panels, for blood cancers  ... by new test, indicate favorable prognosis for patients with ... QIAGEN sees potential for developing companion diagnostics to guide ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... Oct. 28 IRIDEX Corporation (Nasdaq: IRIX ) today ... after the market closes on Thursday, November 4, 2010. ... a conference call with the investment community at 5:00 ... 2010 to discuss the results of the quarter and ...
... SAN DIEGO, Oct. 28 ASTRO Booth # 201 ... will highlight its new TrueBeam™ system for fast, powerful and ... American Society for Radiation Oncology (ASTRO) meeting in San Diego ... as new software capabilities designed to make cancer treatments faster, ...
Cached Medicine Technology:Varian Medical Systems to Exhibit TrueBeam™ System for Image-Guided Cancer Treatments and New Software Capabilities at ASTRO Meeting in San Diego 2Varian Medical Systems to Exhibit TrueBeam™ System for Image-Guided Cancer Treatments and New Software Capabilities at ASTRO Meeting in San Diego 3
(Date:7/27/2014)... 28, 2014 Zensah®, the leader in compression ... include a wrist support . The wrist support features ... area. , Lateral and Medial Epicondylitis, more commonly referred to ... which there is inflammation of the tendons attached to the ... wrist pain, the muscles that work the wrist and fingers ...
(Date:7/27/2014)... Petersburg, FL (PRWEB) July 28, 2014 ... water, and that is the key to the power ... our skin," says Kathy Heshelow, founder of Sublime Beauty®. ... topical Hyaluronic serum such as ours improves skin ... in the skin, key to a healthy and beautiful ...
(Date:7/27/2014)... 2014 Recently, Wdsshop.de, a reliable online supplier ... of fabulous prom dresses on its website. Now, ... up to 58% off. , “We are pleased to add ... They are specially created for those who are in need ... and vivid in style. I think our clients will love ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Bags underneath the ... suffer from globally and there are a range of new ... is now promoting a baggy eyes serum review that is ... , The review explores the issues with baggy eyes and ... appearance for serum users. The guide also provides a detailed ...
Breaking Medicine News(10 mins):Health News:Zensah® Releases New Wrist Support 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2
... serious concern over growing problems due to use of ... Empowerment Meira Kumar today suggested effective monitoring // and ... ,There is a need to establish effective drug use ... the northeastern region,Kumar said while releasing a monograph on ...
... cholesterol-decreasing medications like millions of Americans. However she does ... she is taking part in a different clinical study ... view the benefits of Lipitor on the immune system ... sclerosis (ALS). ,Physicians at the Methodist NI's ...
... 24 years, bled to death following delivery of a stillborn baby, ... mother’s death, would now be offered a ?300,000 compensation for the ... duty in her case. ,She was admitted to the ... told that her baby had passed away in the uterus and ...
... business model for the state-of-the-art Institute of Liver and Biliary ... ,The model approved by the Cabinet at its meeting ... to be self-sufficient in nine years' time, an official spokesman ... medical equipment would be borne by Delhi Government., ,The ...
... ,The effects of zolpidem on three patients were studied for ... rehabilitation experts reveal that they are in a condition where ... interaction and responses, having signs of movement, sleep and breathing ... the patients every morning. ,An improvement was seen ...
... be a ray of hope for men, who are holed ... from available treatment measures//. An exercise by scientists involving rabbits, ... engineer an artificial penis, may be the answer for non-treatable ... adult male rabbits were introduced with a graft made from ...
Cached Medicine News:Health News:Study Aims At The Immune System In Patients With Lou Gehrig's Disease 2Health News:?300,000 Compensation For Family After Death Of Daughter Following Deliver 2
Irrigating Cystotome, Straight, 25 g. Overall length 15 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Medicine Products: